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ABSTRACT

The positive symptoms of schizophrenia primarily result from an excess of
high affinity D2-like receptors (i.e. D2High receptors). First-generation
antipsychotics, such as haloperidol, are D2-like antagonists that can cause
severe extrapyramidal effects. Aripiprazole, a dopamine and serotonin partial
agonist, has fewer side effects, making it tolerable for adults and children.
Extrapyramidal effects (e.g. Parkinsonism, dystonia, and akathisia) are among
the most problematic side effects produced by antipsychotic compounds, which
likely result from an excess of D2-like receptors in the dorsal striatum. In order to
examine the effects of repeated antipsychotic treatment on dopamine system
functioning, this thesis compared the molecular effects of repeated haloperidol
and aripiprazole administration on D2High receptors, as well as various indices of
dopamine second messenger system functioning. Preadolescent and adult rats
were pretreated with haloperidol or aripiprazole for 11 consecutive days. After
either a 4- or 8-day drug abstinence period dorsal striatal tissue was extracted.
[35S]GTPγS binding assays were conducted to assess the effects of repeated
haloperidol and aripiprazole treatment on the efficacy and potency of D2-like
receptors. PKA subunits and components of the Akt pathway were measured
using Western Blots. Results showed that repeated treatment with haloperidol or
aripiprazole did not significantly affect D2-like receptor efficacy or potency in
young or adult rats. In both age groups, haloperidol significantly increased the

iii

expression of PKA-Cα, PKA-Cβ, and PKA-RII, but not p-PKA. Haloperidol also
significantly increased PKA-Cβ and PKA-RII levels relative to aripiprazole.
Repeated administration of haloperidol significantly increased p-GSK-3β levels in
young and adult rats, but neither haloperidol nor aripiprazole significantly affected
GSK-3β, Akt, or p-Akt levels. Overall, the results of this thesis indicate that
repeated aripiprazole and haloperidol treatment differentially affects D2 signaling
pathways in the dorsal striatum. Aripiprazole has less extreme or prolonged
effects on D2 receptor signaling pathways than haloperidol, as evidenced by the
lack of post-treatment upregulation in the cAMP and Akt pathways. Upregulation
of D2-like receptors and, in turn, upregulation of proteins in the cAMP and Akt
pathways may be partially responsible for the side effects induced by long-term
antipsychotic treatment.
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CHAPTER ONE
INTRODUCTION

Approximately 4 out of 1,000 people around the world live with
schizophrenia: a disorder that strains relationships and makes appropriate social
interaction difficult (Stip & Tourjman, 2010). The DSM-V no longer classifies
schizophrenia in categories (paranoid, disorganized, catatonic, undifferentiated,
and residual), but rather it is based on a spectrum of symptoms (Bhati, 2013).
According to the Diagnostic and Statistical Manual of Mental Disorders (5th ed.;
DSM-5; American Psychiatric Association, 2013) diagnosis consists of “two or
more psychotic symptoms for six or more months” that can be acute, ongoing, or
in either partial or full remission (Bhati, 2013). Diagnostic criteria for
schizophrenia include the following symptoms: “delusions (e.g., beliefs not rooted
in reality), hallucinations (e.g., sensory experiences not rooted in reality),
disorganized speech (e.g., incoherent verbal communication), disorganized
behavior or catatonia (e.g., inappropriate or unusual actions or movements), and
negative symptoms (e.g., diminished motivation or behavior)” (American
Psychiatric Association, 2013; Elis, Caponigro, & Kring, 2013, p. 915).
Neural changes underlying these symptoms, as indicated by enlarged
lateral ventricles and lower gray matter volumes in the frontal and medial
temporal lobes, are generally consistent across adult patients (Fusar-Poli et al.,
2013; Shenton, Dickey, Frumin, & McCarley, 2001; Shepard, Laurens, Matheson,
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Carr, & Green, 2012). MRI studies show that neural changes progress as the
brain matures; however, the brains of adults with advanced symptoms of
schizophrenia have similar amounts of damage, suggesting that at some point
during maturation this progression stabilizes (Andreasen et al., 2011; Olabi et al.,
2011; Pantelis et al., 2005). Recent clinical studies have focused on the
prodromal symptoms of schizophrenia in children and adolescents in an attempt
to understand the development of the disorder (Woodberry et al., 2014).
Evidence suggests that there is a strong genetic predisposition for schizophrenia,
and these individuals may be vulnerable to the development of the disorder at
various points during maturation: prenatal, perinatal, childhood, and postadolescence (Cannon, 2005; Pantelis et al., 2005; Walder, Faraone, Glatt,
Tsuang, & Seidman, 2014). Environmental factors, such as prenatal exposure to
infection, malnutrition, toxins, obstetric complications, stress due to social
isolation or familial conflict, brain injury, and drug use, contribute to the onset of
schizophrenia at these vulnerable periods (Brown, 2011; McDonald & Murray,
2000; Seeman & Seeman, 2014).
Although probably involving a complex interplay between various
neurotransmitter systems, the positive symptoms of schizophrenia primarily
result from dopamine system dysfunction. Three brain areas likely to be involved
are the prefrontal cortex, nucleus accumbens, and dorsal striatum (Krug et al.,
2014; Rausch et al., 2014). Clinical efforts focus on reducing dopamine
transmission through the use of dopamine receptor antagonists or partial
2

agonists. Specifically, the D2-like receptors, which include the D2, D3, and D4
subtypes, are linked to schizophrenia (Glatt, Faraone, & Tsuang, 2003; Shafer &
LeVant, 1998; Wang, Zhong, Gu, & Yan, 2003). D2-like receptors can function in
two different states: a state of high affinity and a state of low affinity (i.e. D2 High
and D2Low receptors; Seeman, 2011). Indeed, Seeman (2011) has proposed that
an excess of D2High receptors is responsible for the positive symptoms associated
with schizophrenia.
First-generation antipsychotics or “typical antipsychotics” emerged as a
treatment for schizophrenia in the 1950’s, followed by second-generation antipsychotics or “atypical antipsychotics” in the 1980’s (Abou-Setta et al., 2012).
First-generation antipsychotics are potent dopamine D2-like receptor
antagonists, which exhibit a dose-dependent correlation between clinical
effectiveness and affinity for D2-like receptors (Mailman & Murthy, 2010). Despite
their clinical efficacy, first-generation antipsychotics have many undesirable side
effects, including sedation, autonomic and cardiovascular changes, weight gain,
extrapyramidal side effects (i.e. Parkinsonism, dystonia, and akathisia),
neuroendocrine effects, and tardive dyskinesia (Mailman & Murthy, 2010).
Extrapyramidal side effects can become permanent, and the acetylcholinergic
drugs used to treat these motor deficits have their own set of side effects (dry
mouth, constipation, delirium, and memory problems) (Mailman & Murthy, 2010).
As a consequence, many patients are reluctant to take first-generation
antipsychotics, as evidenced by the number of patients who stop long-term
3

treatment (Warikoo, Chakrabarti, & Grover, 2014); thus making the search for an
effective antipsychotic with few complications both necessary and complex.
Second-generation antipsychotics (such as amisulpride, clozapine,
olanzapine, and risperidone) cause a reduction of positive symptoms, and
produce fewer side effects than first-generation antipsychotics (Croxtall, 2012;
Leucht et al., 2009). Even so, second-generation antipsychotics do have some
side effects, such as weight gain, myocarditis, sexual dysfunction, and acute
extrapyramidal symptoms (Gardner, Baldessarini, & Waraich, 2005; Shirzadi &
Ghaemi, 2006; Uçok & Gaebel, 2008). Patients may be just as likely to
discontinue taking second-generation antipsychotics as first-generation
antipsychotics, since long-term preference for either first- or second-generation
drugs remains inconclusive (Warikoo et al., 2014). Overall, first- and secondgeneration antipsychotics appear about equally effective at mitigating positive
symptoms, but neither are particularly effective at reducing negative symptoms
(Leucht et al., 2009; McEvoy, Zygman, & Margolese, 2010; White et al., 2006).
Today, 20 first-generation and second-generation antipsychotics are approved by
the Food and Drug Administration for the treatment of schizophrenia, and some
drugs are used off-label for the treatment of other disorders (Abou-Setta et al.,
2012).
Despite these advances, there is a continuing desire to develop drugs with
a superior side effect profile and a greater efficacy for treating negative
symptoms. Aripiprazole is a dopamine and serotonin partial agonist with a high
4

affinity for D2-like receptors, thus placing it in a class of its own as a “thirdgeneration” antipsychotic. Aripiprazole is recognized throughout the literature for
its efficacy, tolerability among patients, and its ability to reduce symptoms of
other mental disorders, including off-label use for severe agitation in geriatric
dementia patients (Leslie, Mohamed, & Rosenheck, 2009; Maglione et al., 2009;
Shekelle et al., 2007). Additionally, aripiprazole may be more effective than other
drugs at treating negative symptoms (DeLeon, Patel, & Crismon, 2004; Naber &
Lambert, 2004; Stip & Tourjman, 2010), although some studies suggest that
aripiprazole and second-generation antipsychotics do not differ according to
negative symptom reduction (Bianchini et al., 2014). According to Kirino (2012)
aripiprazole has fewer side effects than other antipsychotics, although some
aversive symptoms have been reported. Interestingly, actions at serotonin
receptors may be involved in the muted extrapyramidal effects experienced after
repeated aripiprazole treatment, since serotonin receptor antagonism increases
dopaminergic transmission and, thus, could soften dopamine receptor
upregulation in the dorsal striatum (Kapur & Mamo, 2003; Kuroki, Nagao, &
Nakahara, 2008; Meltzer, Li, Kaneda, & Ichikawa, 2003). Aripiprazole was
approved by the Food and Drug Administration in 2002 for the treatment of
schizophrenia (Kirino, 2012).
Due to the high tolerability of aripiprazole, it is also administered to
children and adolescents diagnosed with schizophrenia (ages 13-17) and bipolar
disorder I (ages 10-17), either alone or in conjunction with lithium or valproate
5

(Kirino, 2012). Aripiprazole has also been administered to children for tic
disorders, autism, aggression or conduct disorder, and depression (Masi et al.,
2009; Stachnik & Nunn-Thompson, 2007; Yoo et al., 2011). The few studies
assessing the long-term effects of aripiprazole in children are promising. Yoo et
al. (2011) compared the effects of the first-generation antipsychotic haloperidol to
aripiprazole, and found that the two drugs were equally efficacious at reducing tic
symptoms, but aripiprazole had fewer side effects.
In summary, haloperidol and aripiprazole are equally effective at reducing
positive symptoms in patients with schizophrenia, with aripiprazole being more
efficacious when treating negative symptoms. Haloperidol is associated with
pronounced side effects, most notably hyperprolactinemia and extrapyramidal
symptoms; whereas, the development of hyperprolactinemia, weight gain, and
sedation is generally much lower with aripiprazole (Kane et al., 2002; Marder et
al., 2003; McEvoy, Daniel, Carson, McQuade, & Marcus, 2007). With this
information as a backdrop, the purpose of this thesis is to compare the effects of
haloperidol and aripiprazole at a molecular level across ontogeny, in order to
determine the basis for these different treatment outcomes in humans. To this
end, I assessed the effects of haloperidol and aripiprazole on D2High receptors
and various indices of second messenger system functioning (e.g. protein kinase
A subunits and Akt levels). Understanding the neuronal effects of these
compounds in preadolescent and adult rats could help explain the unique
treatment and side effect profiles of first-, second-, and third-generation
6

antipsychotics and expose potential ontogenetic differences in receptor
functioning.
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CHAPTER TWO
DOPAMINE SYSTEMS IN ADULT RODENTS

Overview of Dopamine Pathways and Schizophrenia
The mammalian brain contains four prominent dopamine pathways:
nigrostriatal, mesolimbic, mesocortical, and tuberoinfundibular. Dysregulation of
dopamine systems within two of these pathways is thought to underlie the
symptoms of schizophrenia (Davis, Kahn, Ko, & Davidson, 1991). The positive
symptoms of schizophrenia are attributed to hyperdopaminergia in the
mesolimbic pathway, while negative symptoms are attributed to
hypodopaminergia in the mesocortical pathway (Davis et al., 1991). Additionally,
dopamine antagonism in the nigrostriatal dopamine pathway is responsible for
extrapyramidal side effects (Nguyen, Pradel, Micallef, Montastruc, & Blin, 2004;
Ossowska, 2002).
Dahlström and Fuxe (1964) categorized dopaminergic cells into nine
clusters within the rat brain, with higher concentrations of dopamine in the rostral
mesencephalon and lower concentrations of dopamine in the diencephalon. This
patterning suggests that dopamine fibers project from caudal to rostral areas
(Dahlström & Fuxe, 1964). Further research showed that clusters of cells
containing high levels of dopamine originate in the ventral tegmental area and
the substantia nigra pars compacta (Beckstead, Domesick, & Nauta, 1979;
Moore & Bloom, 1978; Smith & Kieval, 2000). The axons of cells located in the
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ventral tegmental area extend to the ventral striatum (nucleus accumbens), and
are referred to as the mesolimbic pathway (Björklund & Dunnett, 2007). Some
neurons project directly from the ventral tegmental area to the prefrontal cortex,
and this pathway is known as the mesocortical pathway (Emson & Koob, 1978;
Fuxe et al., 1974). The two pathways projecting to the nucleus accumbens are
sometimes jointly referred to as the mesocorticolimbic pathway (White, 1996).
The axons of cells located in the substantia nigra terminate in the dorsal striatum
(caudate nucleus and putamen), which is known as the nigrostriatal pathway
(Hanley & Bolam, 1997; Matsuda et al., 2009; Prensa & Parent, 2001). A fourth
pathway, labeled the tuberoinfundibular pathway, projects from the hypothalamus
to the anterior pituitary (Ben-Jonathan, Arbogast, & Hyde, 1989; Gudelsky, 1981;
McCann et al., 1986).

Mesolimbic Pathway
Ventral Tegmental Area
Dorsal to the substantia nigra, the ventral tegmental area is involved in
reward, motivation, and cognition (Lewis & O’Donnell, 2000). The ventral
tegmental area is divided into four sections: the paranigral nucleus, the
parabrachial pigmented area, the parafasciculus retroflexus area, and the ventral
tegmental tail (Oades & Halliday, 1987). Both the paranigral and parabrachial
pigmented areas contain high concentrations of dopaminergic cells, whereas the
parafasciculus retroflexus area and the ventral tegmental tail contain much lower
9

concentrations (Ikemoto, 2007). The ventral tegmental tail contains GABAergic
neurons that inhibit the firing of dopaminergic neurons within other portions of the
ventral tegmental area. The prominent tract projecting from the ventral tegmental
area innervates the nucleus accumbens, olfactory tubercle, amygdala, septal
area, and the anterior limbic area (Ikemoto, 2007; Swanson, 1982).
Nucleus Accumbens
The nucleus accumbens, also known as the ventral striatum, is composed
of a core and a shell (Heimer, Zahm, Churchill, Kalivas, & Wohltmann, 1991).
Dopaminergic cells are robustly located in the shell, with few dopaminergic
neurons found in the core (Deuscht & Cameron, 1992; Zahm, 1992).
Dopaminergic afferents innervate the shell from the ventral tegmental tail in
addition to limbic structures such as the hippocampus, lateral hypothalamus,
entorhinal cortex, and amygdala (Deuscht & Cameron, 1992). Neurons located in
the shell exhibit two main structural distinctions from neurons in the core.
Namely, neurons in the shell have fewer dendritic spines and fewer terminals
than do neurons located in the core (Meredith, Agolia, Arts, Groenewegen, &
Zahm, 1992). Evidence suggests that dopaminergic release in the nucleus
accumbens is modulated by glutamatergic afferents from the prefrontal cortex
and the basal lateral amygdala (Jackson & Moghaddam, 2001).
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Mesocortical Pathway
Neurons that comprise the mesocortical pathway project from the ventral
tegmental area to limbic and medial prefrontal cortices (Björklund & Dunnett,
2007; Voorn, Jorritsma-Byham, Van Dijk, & Buijs, 1986). Most notably, neurons
in the paranigral and parabrachial nuclei of the ventral tegmental area project to
the medial prefrontal cortex (Lammel et al., 2008; Oades & Halliday, 1987;
Ranganath & Jacob, 2015). The medial prefrontal cortex is located in the most
rostral area of the brain near the midline. In rats, it is functionally involved in
working memory, attention, and inhibitory response control, although cognitive
abilities associated with the prefrontal cortex vary among species (Dalley,
Cardinal, & Robbins, 2004; Heidbreder & Groenwegen, 2003; Ranganath &
Jacob, 2015). In addition to these more prominent limbic and cortical projections,
neurons originating in the ventral tegmental area also terminate in the thalamus,
periaqueductal gray, parabrachial nucleus, locus coeruleus, and the median
raphe nucleus (Swanson, 1982).

Nigrostriatal Pathway
Substantia Nigra
The substantia nigra contains a large concentration of dopaminergic
neurons. It is subdivided into two nuclei: the substantia nigra pars compacta and
the nondopaminergic substantia nigra pars reticulata. The pars compacta and
pars reticulata are associated with the control of voluntary movement.
11

Dopaminergic neurons located in the substantia nigra pars compacta project to
the dorsal striatum (caudate nucleus and putamen), globus pallidus, and
entopeduncular nucleus (Gauthier, Parent, Lévesque, & Parent, 1999; Gerfen,
Staines, Fibiger, & Arbuthnott, 1982). A higher concentration of these neuronal
cell bodies reside in the rostral portion of the substantia nigra pars compacta in
comparison to the caudal region (Tieu, 2011).
Dorsal Striatum
The caudate nucleus, which is a component of the dorsal striatum, is
essential for the control of voluntary movement. The caudate nucleus lies
adjacent to the thalamus and the anterior horn of the lateral ventricle.
Dopaminergic efferents from the substantia nigra terminate in the caudate
nucleus (Gauthier, Parent, Lévesque, & Parent, 1999; Matsuda et al., 2009;
Nelson & Kreitzer, 2014), with outputs extending to the subthalamic nucleus and
globus pallidus. The putamen, a second component of the dorsal striatum, also
plays a critical role in the regulation of voluntary movement, and it is structurally
and functionally associated with the caudate nucleus in rodents.
Subthalamic Nucleus
The subthalamic nucleus consists mainly of glutamatergic neurons that
have a modulatory effect on dopamine pathways. Located posteromedially to the
substantia nigra, the subthalamic nucleus modulates voluntary movement, as
lesions to the subthalamic nucleus result in contralateral hemiballismus (Hamani,
Saint-Cyr, Fraser, Kaplitt, & Lozano, 2004). The subthalamic nucleus receives
12

dopaminergic input from the dorsal striatum, and maintains a feedback loop with
the globus pallidus.
Globus Pallidus
The globus pallidus is an integrated structure in rats, whereas in primates
the globus pallidus has distinct external and internal components. The globus
pallidus is located caudally to the dorsal striatum and is involved in controlling
voluntary movement. The globus pallidus receives afferents from the substantia
nigra, caudate nucleus, putamen, and subthalamic nucleus (Kita & Kita, 2001).
GABAergic neurons in the globus pallidus project to the lateral and anterior
nuclei of the thalamus and the subthalamic nucleus (Bevan, Booth, Eaton, &
Bolam, 1998).
Entopeduncular Nucleus
The entopeduncular nucleus can be found in non-primate mammals and is
located lateral to the hypothalamus. This area corresponds to the medial
pallidum in primates (Benhamou & Cohen, 2014), and is functionally similar to
the globus pallidus. The entopeduncular nucleus receives dopaminergic afferents
from the substantia nigra pars compacta and projects GABAeric fibers to the
thalamus.
Thalamus
The thalamus is comprised of nuclei that synthesize information about
sensory stimuli and voluntary movement. Among the many nuclei, the
ventromedial nucleus of the thalamus is involved in motor control in rats (Clavier,
13

Atmadja, & Fibiger, 1976). Efferents from the putamen and entopeduncular
nucleus converge in the ventromedial thalamus, while outputs from the thalamus
project to the supplementary motor area, the cerebellum, and the spinal cord.

Tuberoinfundibular Pathway
Hypothalamus
The hypothalamus is located below the thalamus and is a highly
interconnected region comprised of many small nuclei involved in the regulation
of the endocrine system and other homeostatic mechanisms (DeGroot, 1959;
Reichlin, Saperstein, Jackson, Boyd, & Patel, 1976). As a consequence, the
hypothalamus regulates the sympathetic nervous system and modulates stress,
sleep, body temperature, physical growth, metabolism, sexual maturation,
ovulation and spermatogenesis, lactation, hunger, and thirst (Besser & Mortimer,
1974; Schally, Kastin, & Arimura, 1977). The tuberoinfundibular pathway, which
projects from the arcuate and paraventricular nuclei of the hypothalamus to the
anterior pituitary, releases dopamine at the target site.
Anterior Pituitary
The pituitary gland contains an anterior lobe (adenohypophysis) and a
posterior lobe (neurohypophysis). The neurosecretory cells in the anterior lobe
release various hormones into the blood (e.g. growth hormone, luteinizing
hormone, follicle-stimulating hormone, thyroid-stimulating hormone, ACTH, and
prolactin) (Ben-Jonathan, Arbogast, & Hyde, 1989; Besser & Mortimer, 1974;
14

Buckingham, 1981; Schally et al., 1977). Dopaminergic efferents from the
tuberoinfundibular pathway inhibit the release of prolactin (Enjalbert et al., 1986;
Macleod & Lehmeyer, 1974; Maurer, 1980). Prolactin is primarily known for
inducing lactation in mammals, but also regulates water and electrolyte balance,
growth, metabolism, parental behavior, reproduction, and immunoregulation
(Bole-Feysot et al., 1998).
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CHAPTER THREE
DOPAMINE RECEPTORS IN ADULT RODENTS

Dopamine Receptor Subtypes and the cAMP Signaling Pathway
Dopamine receptors are relatively homologous, but they are classified
functionally based on their modulation of adenylyl cyclase via G protein coupled
receptors (Beaulieu & Gainetdinov, 2011; Missale, Nash, Robinson, Jaber, &
Caron, 1998). D1-like receptors include both D1 receptors (D1A receptors in rats)
and D5 receptors (D1B receptors in rats) (Emilien, Maloteaux, Geurts,
Hoogenberg, & Cragg, 1999). When an agonist binds to D1 or D5 receptors, Gsα
and Golfα subunits detach from the β and γ subunits through the exchange of
guanosine diphosphate (GDP) for guanosine triphosphate (GTP). This triggers
an increase in adenylyl cyclase activity, which causes adenosine triphosphate
(ATP) to lose two phosphate groups and become adenosine monophosphate, or
cyclic AMP (cAMP). Cyclic AMP stimulates protein kinase A (PKA), which
consequently regulates protein transcription and gene expression.
Receptors in the D2-like subclass, which include D2, D3, and D4 receptors,
activate the G protein subunit Giα. As the Giα subunit dissociates from the βγ
complex, through the exchange of GDP for GTP, adenylyl cyclase is inhibited.
Inhibition of adenylyl cyclase results in decreased cAMP levels and PKA activity
which, in turn, suppresses protein transcription and gene expression (Beaulieu &
Gainetdinov, 2011; Missale et al., 1998). Thus, PKA is active when cAMP binds
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to the PKA regulatory subunit, causing the alpha and beta catalytic subunits to
separate (Dell’Acqua & Scott, 1997; Hubbard & Cohen, 1993).

D2 Receptors and the Akt Signaling Pathway
Akt, also referred to as Protein Kinase B, is a serine/threonine kinase that
is part of a D2 receptor second messenger cascade involved in the gene
regulation of cell proliferation and apoptosis (Brunet, Datta, & Greenberg, 2001;
Kennedy et al., 1997; Song, Ouyang, & Bao, 2005). Thus, this pathway plays an
important role in normal functioning of dopamine-regulated behaviors and is
distinct from the cAMP pathway (Arguello & Gogos, 2008; Li & Gao, 2011).
Activation of the Akt signaling pathway appears to be unique to D2 receptors, but
may be augmented by D3 receptors (Beaulieu et al., 2007). When dopamine
binds to D2 receptors, the phosphorylation of Giα by G protein receptor kinases
signals β-arrestin2 to activate protein phosphatase 2A (PP2A). PP2A inhibits Akt,
which inhibits glycogen synthase kinase 3 (GSK-3β) (Beaulieu, Del’Guidice,
Sotnikova, Lemasson, & Gainetdinov, 2011; Li & Gao, 2011). GSK-3β, in turn,
inhibits β-catenin. Evidence suggests that the Akt signaling pathway is active
under hyperdopaminergic conditions, and β-catenin may mediate synaptic
plasticity via glutamatergic AMPA and NMDA receptors (Li & Gao, 2011). When
D2 receptors are stimulated by an agonist, the inhibitory effects of GSK-3β on βcatenin are disinhibited due to the inhibition of Akt by PP2A, thus attenuating the
modulatory effects of β-catenin (Beaulieu et al., 2011).
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D1-like Receptor Localization
In terms of the D1-like receptor family, D1 receptors are the most prolific
dopamine receptor subtype and are found densely in the striatum, nucleus
accumbens, substantia nigra pars reticulata, olfactory bulb, amygdala, frontal
cortex, hippocampus, cerebellum, thalamus, and hypothalamus (Beaulieu &
Gainetdinov, 2011; Dawson, Ghelert, Yamamura, Barnett, & Wamsley, 1985).
High concentrations of D1 receptors are found in the entopenduncular nucleus
and the islands of Calleja, with moderate to low concentrations in the frontal
cortex and subthalamic nucleus (Dawson et al., 1985; Emilien et al., 1999).
Additionally, high levels of D1 receptor mRNA are located in the striatum, nucleus
accumbens, olfactory tubercle, amygdala, and anterior cingulate cortex (MeadorWoodruff, 1991, 1994). Low levels of D1 mRNA are found in the septum,
hippocampus, hypothalamus, thalamus, cerebellum, and cortex (MeadorWoodruff, 1991, 1994).
D5 receptors are less abundant than other dopamine receptor subtypes
and are found primarily on pyramidal neurons of the prefrontal cortex, premotor
cortex, cingulate cortex, entorhinal cortex, olfactory tubercle, substantia nigra
pars compacta, hypothalamus, hippocampus, and dentate gyrus (Beaulieu &
Gainetdinov, 2011). Relatively low levels of D5 receptors are also located on the
medium spiny neurons of the caudate nucleus and the nucleus accumbens
(Beaulieu & Gainetdinov, 2011; Khan et al., 2000). Moderate levels of D5
receptor mRNA are detected in the parafascicular nucleus of the thalamus and
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hippocampus (Meador-Woodruff, 1992, 1994). Additionally, high levels of D5
receptor mRNA are found in the endoperiform, reuniens and perifascicular nuclei
of the thalamus (Apostolakis et al., 1996).

D2-like Receptor Localization
D2 receptors are the most abundant of the D2-like receptors and are found
in many of the same locations as D1 receptors (Boyson, McGonigle, & Molinoff,
1986). Higher concentrations of D2 receptors are evident in the striatum, nucleus
accumbens, olfactory tubercle, substantia nigra, ventral tegmental area,
hypothalamus, striate cortex, entorhinal cortex, choroid plexus, islands of Calleja,
septum, amygdala, hippocampus, pituitary gland, and retina (Boyson et al., 1986;
Charuchinda, Supavilai, Karobath, & Palacios, 1987; Gehlert & Wamsley, 1986).
D2 receptor mRNA is abundant in the substantia nigra, ventral tegmental area,
and zona incerta (Meador-Woodruff, 1991, 1994). Additionally, high levels of D2
mRNA are located in the striatum, nucleus accumbens, olfactory tubercle, and
entorhinal cortex, with moderate levels in the anterior cingulate, orbital and
insular cortices. In contrast, low levels of D2 receptor mRNA are found in the
septum, amygdala, hippocampus, cortex, hypothalamus, thalamus, and
cerebellum (Meador-Woodruff, 1991, 1994). D2 receptors have two distinct
isoforms: D2 short (D2S) and D2 long (D2L). D2S receptors are located
presynaptically and function as dopamine autoreceptors, whereas D2L receptors
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are located postsynaptically (Jomphe, Tiberi, & Trudeau, 2005; Lindgren et al.,
2003; Usiello et al., 2000).
The highest densities of D3 receptors are predominately found in the shell
of the nucleus accumbens, olfactory tubercle, islands of Calleja, ventral pallidum,
substantia nigra, and cerebellum (Lévesque et al.,1992; Stanwood et al., 2000).
Lower numbers of D3 receptors are found in the striatum, ventral tegmental area,
hippocampus, septum, and prefrontal cortex (Beaulieu & Gainetdinov, 2011;
Lévesque et al.,1992). Not surprisingly, D3 receptor mRNA is highly expressed in
the nucleus accumbens and islands of Calleja, with low levels in the substantia
nigra, ventral tegmental area, striatum, septum, olfactory tubercle, amygdala,
hippocampus, cortex, hypothalamus, thalamus, and cerebellum (Lévesque et
al.,1992; Meador-Woodruff, 1991, 1994).
D4 receptors are the least common of the D2-like receptors and are
expressed in relatively low levels in the hippocampus, striatum, olfactory
tubercle, amygdala, hypothalamus, globus pallidus, substantia nigra, nucleus
accumbens core, thalamus, frontal and entorhinal cortices, and cerebellum
(Defagot & Antonelli, 1996; Defagot, Malchiodi, Villar, & Antonelli, 1997; Primus
et al., 1997; Tarazi, Kula, & Baldessarini, 1997). D4 receptor mRNA is located in
the substantia nigra and ventral tegmental area (Meador-Woodruff, 1994), while
low levels of D4 receptor mRNA are expressed in the nucleus accumbens,
amygdala, hippocampus, cortex, hypothalamus, and thalamus (MeadorWoodruff, 1994).
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D2High Receptor Affinity and Functionality
As mentioned in Chapter 1, D2-like receptor systems are intimately
associated with psychosis. D2-like receptors exist in two different functional
states: a state of high affinity and a state of low affinity (Seeman, 2011). The
high-affinity state of the D2-like receptor, known as D2High, is thought to be
responsible for dopamine supersensitivity, which is most commonly observed as
an exaggerated behavioral response to agonist drugs. Various manipulations
increase D2High receptors and produce dopamine supersensitivity, including
ethanol treatment and withdrawal, hippocampal lesion, amphetamine- or
quinpirole-induced sensitization, Cesarean section, cocaine self-administration,
and excitotoxic lesions of the entorhinal cortex (Briand, Flagel, Seeman,
Robinson, 2008; Seeman et al., 2005; Sumiyoshi et al., 2005). Among humans,
dopamine agonists can trigger psychotic symptoms in normal populations and
exacerbate psychosis in schizophrenics (Angrist, Rotrosen, & Gershon, 1980;
Bell, 1973; Ellison, 1994). Thus, the positive symptoms characteristic of
schizophrenia may not result from a simple increase in D2-like receptor numbers
in particular dopaminergic pathways, but rather a change in the functionality of
the D2-like receptors. Specifically, Seeman (2011) has proposed that an
increased proportion of D2High receptors relative to D2Low receptors is responsible
for schizophrenia. Therefore, an increased percentage of D2High receptors may
underlie the hyperdopaminergia of the mesolimbic dopamine pathway (Davis et
al., 1991).
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CHAPTER FOUR
DOPAMINE SYSTEMS AND RECEPTORS IN YOUNG RODENTS

Overview
Dopamine neurons increase steadily in number from the prenatal period
through adolescence (Tarazi & Baldessarini, 2000). Around PD40, dopamine
receptor levels peak and a period of pruning occurs in which receptors decline to
adult levels at PD60 through PD120 (Andersen, Thompson, Rutstein, Hostetter,
& Teicher, 2000; Teicher, Andersen, & Hostetter, 1995). Dopamine neurons are
apparent at embryonic day (E)13 in the prosencephalon; and by E14 two
prominent clusters of dopamine neurons extend from the mesencephalon to the
ganglionic eminence (Voorn, Kalsbeek, Jorritsma-Byham, & Groenewegen,
1988). By E17, these trajectories innervate the dorsal striatum, and dopamine
neurons further differentiate into distinct clusters that form the substantia nigra,
VTA, dorsal striatum, nucleus accumbens, and olfactory tubercles (Fishell & van
der Kooy, 1987; Voorn et al., 1988). Rostral dopaminergic afferents also spread
to the area of the future prefrontal cortex (Kalsbeek, Voorn, Buijs, Pool, &
Uylings, 1988). Dopamine neurotransmitter levels during early development (E18
to PD5) are about 8-17% of adult levels (Noisin & Thomas, 1988).
By the first postnatal day (PD1), dopamine neurons in the substantia nigra
exist in small distinct clusters. These clusters more closely resemble adult
distributions by PD4 and continue to increase in size through PD11 (Fishell & van
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der Kooy, 1987; Murrin & Ferrer, 1984). Around PD4, dopamine neurons
innervate the nascent prefrontal cortex (Kalsbeek et al., 1988). Dopamine
neurons throughout the dorsal striatum continue to develop from PD8 through
PD13 (Voorn et al., 1988). A shift in development occurs in the dorsal striatum
during adolescence, as dopamine receptor levels peak at PD40 and then decline
to adult levels by PD60 (Teicher et al., 1995). This developmental pattern is
apparent in the dorsal striatum, but similar changes in receptor density are also
observed in the nucleus accumbens (Teicher et al., 1995). Overall, dopamine
neurotransmitter levels fluctuate during development and are heterogeneous
across brain areas. Dopamine levels eventually stabilize at adult levels at
different time points depending on brain region, but adult dopaminergic systems
are established by PD120 (Andersen et al., 2000; Rao, Molinoff, & Joyce, 1991).

Overview of Dopamine Receptor Subtype Development
In the dorsal striatum, D1-like and D2-like receptors increase at similar
rates, thus suggesting that development of the two receptor subtypes are
controlled by similar mechanisms (Zeng, Hyttel, & Murrin, 1988). Despite a
general increase in receptors with age, the emergence of D1-like and D2-like
receptors is non-linear, since the dorsal striatum, substantia nigra, and globus
pallidus contain heterogeneous levels of receptor subtypes at any given age
(Rao et al., 1991). Within the dorsal striatum and nucleus accumbens, D1, D2,
and D4 receptors reach peak levels at PD28 and decline to adult levels between
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PD35 and PD60 (Tarazi & Baldessarini, 2000). Limbic and cortical structures
also demonstrate a similar developmental pattern, with a relative absence of
pruning during adolescence (Tarazi & Baldessarini, 2000). D1 and D2 receptor
mRNA is apparent before dopaminergic innervation, however postnatal
dopamine receptor binding correlates with dopamine innervation (Jung &
Bennett, 1996). At birth, D1-like and D2-like receptor mRNA is at about 60% of
adult levels, with mRNA levels peaking at PD30, and then declining to adult
levels (Creese, Sibley, & Xu, 1992).

D1-like Receptor Localization
Embryonic development of D1-like receptors increases slowly from E14
through birth (Jung & Bennett, 1996). Early evidence suggested that the number
of D1-like receptors stabilizes between birth and seven postnatal weeks
(Broaddus & Bennett, 1989); however, it is more generally reported that D1-like
receptors double in number every 7 to 10 days for the first 3 weeks (Murrin &
Zeng, 1990; Zeng et al., 1988). This pattern of development is clearly evident in
areas such as the dorsal striatum, nucleus accumbens, and olfactory tubercle,
but the same pattern is also apparent in brain regions with more moderate levels
of D1-like receptors such as the frontal cortex, claustrum, and endoperiform
nucleus (Murrin & Zeng, 1990). The function of the D1-like receptor is unaltered
during maturation, since juvenile D1-like receptors exhibit the same
pharmacological properties as adult D1-like receptors (Zeng et al., 1988). For
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example, D1-like receptors are coupled to their G-proteins by PD5 (Jung &
Bennett, 1996). D1-like receptor levels increase steadily throughout the
developing brain until adolescence. At PD40, D1-like receptor densities in the
dorsal striatum peak and then decline to adult levels where they remain relatively
stable from PD60 through PD140 (Teicher et al., 1995). D1-like receptor mRNA
is apparent by E14 in the dorsal striatum, olfactory tubercle, frontal, cingulate,
parietal, and insular cortices, epithalamus, thalamus, hypothalamus, and pons.
By E18, mRNA localization parallels that of adults (Schambra et al., 1994). In the
nigrostriatal pathway, D1-like receptor mRNA increases linearly until birth, peaks
at PD5, and then decreases by 20% until adult levels are maintained (Jung &
Bennett, 1996).

D2-like Receptor Localization
D2 receptors are the most abundant and diffuse of the D2 receptor family
(Stanwood, McElligot, Lu, & McGonigle, 1997). Even so, most studies examining
the ontogeny of D2-like receptors use displacing ligands that do not differentiate
among the D2-like receptor subtypes. Despite this issue, D2-like receptor
autoradiography is a good estimate of D2 receptor distribution due to the
relatively large number of D2 receptors compared to D3 and D4 receptors
(Stanwood et al., 1997). At E12, D2-like receptors are found in the caudal part of
the neural tube and extend outward to regions that will comprise the forebrain.
This pattern of development leads to a dramatic increase in the number of dorsal
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striatal receptors between E15 through E17 (Sales, Martres, Bouthenet, &
Schwartz, 1989). Large increases in D2-like receptor levels occur from E18
through E22 across the forebrain, and this late prenatal period is also
characterized by the emergence of D2-like receptors in the olfactory tubercles
(Sales et al., 1989). Generally, D2-like receptors increase linearly in number from
PD2, and approach adult levels by PD21 (Murrin & Zeng, 1986; Stanwood et al.,
1997). D2-like receptor numbers and G-protein-induced inhibition of adenylyl
cyclase increases between PD21 through PD28, which coincides with a
substantial increase in dopamine terminals in the dorsal striatum (Broaddus &
Bennett, 1989). In terms of D2-like receptor subtypes, expression of D2 receptors
antecedes expression of D3 receptors, since D3 receptors emerge at a slower
rate in the dorsal striatum and nucleus accumbens than D2 receptors (Stanwood
et al., 1997). D3 receptors are detectable by PD14 in the islands of Calleja and by
PD21 in the nucleus accumbens. D3 receptors show a steady increase in
numbers until PD60 (Stanwood et al., 1997). In terms of receptor affinity, the D2like receptors of young and adult rats show a similar binding affinity (i.e. Kd) by
PD7 (Murrin & Zeng, 1986).
D2-like receptor mRNA is present at E14 in the dorsal striatum, olfactory
tubercle, frontal, cingulate, parietal, and insular cortices, epithalamus, thalamus,
hypothalamus, and pons (Schambra et al., 1994; Srivastava, Morency, & Mishra,
1992). At E18, D2-like receptor mRNA dispersion is similar to what is observed in
adult rat brains, although D2-like receptor mRNA levels show a different pattern
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of development depending on brain region (Schambra et al., 1994). For example,
in most brain areas D2-like receptor mRNA increases steadily until adulthood,
although some studies report a slight decline in the dorsal striatum between
PD16 and PD28 (Chen & Weiss, 1991; Jung & Bennett, 1996; Srivastava et al.,
1992; Weiss, Chen, Zhang, & Zhou, 1992). In contrast, D2-like receptor mRNA in
the midbrain peaks by PD14 and then declines to adult levels (Creese et al.,
1992).

D2High Receptors and Measures of D2 Functionality
Evidence suggests that there are ontogenetic changes in the functional
state of D2-like receptors. A study by McDougall et al. (2015) assessed the
number of D2High receptors in preadolescent, adolescent, and adult rats. Their
results indicated that the percentage of D2High receptors in the dorsal striatum of
preadolescent rats was twice that of adolescent (PD40) and adult (PD80) rats,
although there were no differences in the percentage of D2 High receptors between
the various preadolescent ages (PD5, PD10, PD15, PD20). In an experiment
particularly important to this thesis, we examined the effects of haloperidol and
aripiprazole on the dorsal striatal D2High receptors of young rats. Haloperidol and
aripiprazole was administered via intraperitoneal injection from PD10 through
PD20. Following either a 4 or 8 day drug abstinence period, dorsal striatal tissue
was extracted and analyzed via dopamine competition assays using
[3H]domperidone. Regardless of drug abstinence period, our results indicated
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that both haloperidol and aripiprazole significantly increased the percentage of
D2High receptors in the dorsal striatum of preadolescent rats. Thus, these results
demonstrate that antipsychotic drugs can alter D2High receptors during early
development as well as in adulthood (Seeman, 2008).
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CHAPTER FIVE
EFFECTS OF REPEATED TREATMENT WITH DOPAMINE COMPOUNDS
ON D2 RECEPTORS

Overview
Evidence suggests that as many as 70% of people with schizophrenia are
supersensitive to dopamine agonists, as evidenced by agonist-induced
exacerbation of psychotic symptomology (Lieberman, Kane, & Alvir, 1987).
Supersensitivity is not simply due to an increase in the quantity of D2-like
receptors, but it can be caused by changes in the functional state of the receptor
(Seeman et al., 2005). Repeated treatment with dopamine antagonists,
especially first-generation antipsychotics, can cause dopamine receptor
upregulation (Burt, Creese, & Snyder, 1977; Laruelle et al., 1992; O’Dell et al.,
1990; Wilmot & Szczepanik, 1989). Upregulation is manifested as an increase in
the number of dopamine receptors, which results from dopamine denervation or
prolonged pharmacological blockade of dopamine receptors (Ginovart, Wilson,
Hussey, Houle, & Kapur, 2008; Seeman, Lee, Chau-Wong, & Wong, 1976;
Staunton, Magistretti, Koob, Shoemaker, & Bloom, 1982). The behavioral impact
of dopamine receptor upregulation often takes the form of extrapyramidal side
effects or tardive dyskinesia (Creese & Snyder, 1980; Klawans & Rubovitz, 1972;
Tarsy & Baldessarini, 1977). Repeated treatment with second-generation
antipsychotics results in an upregulation of D2-like receptors, but long-term
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extrapyramidal side effects do not appear as severe. Kapur and Seeman (2014)
proposed that the lack of side effects may be due to the fast dissociation of these
compounds at D2-like receptors, although the more favorable treatment outcome
of second-generation antipsychotics has yet to be fully explained (Dwivedi,
Rizavi, & Pandey, 2002). The third-generation antipsychotic aripiprazole is
thought to be more of a “stabilizer” of receptor activity, thus resulting in fewer
side effects in people with schizophrenia (Kirino, 2012). There is conflicting
evidence as to whether aripiprazole causes D2-like receptor upregulation in the
dorsal striatum, since either no changes or slight increases in D2 receptor
numbers have been reported (Inoue et al., 1997; Tadokoro et al., 2012).

Effects of Repeated Haloperidol or Aripiprazole Treatment on D2-like Receptors
in the Dorsal Striatum of Adult Rodents
Upregulation of D2-like Receptors
It is well established that repeated treatment with haloperidol causes an
upregulation of D2-like receptors in the dorsal striatum. Following 21 days of
haloperidol treatment, D2-like receptors in the dorsal striatum increase by
approximately 50% (O’Dell et al., 1990; Wilmot & Szczepanik, 1989). When
combined with denervation of dopamine neurons, repeated treatment with
haloperidol leads to even greater increases in D2-like receptor numbers (Reches,
Wagner, Jackson, Yablonskaya-Alter, & Fahn, 1983; Shaunton, Magistretti,
Koob, Shoemaker, & Bloom, 1982). In general, studies comparing the effects of
repeated haloperidol and aripiprazole treatment conclude that the first-generation
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antipsychotic is much more likely to induce D2-like receptor upregulation.
Following repeated administration of haloperidol (1, 2, or 4 mg/kg) or aripiprazole
(12 or 100 mg/kg) for 21 days, haloperidol caused a 40% increase in dorsal
striatal D2-like receptors (i.e. Bmax values). In contrast, aripiprazole produces only
a nonsignificant upregulation of D2 receptors when compared to control values,
suggesting that aripiprazole acts as an antagonist at dorsal striatal D2 receptors
regardless of its potency (12 or 100 mg/kg) (Inoue et al., 1997). In a similar
study, Tadokoro et al. (2012) showed that a 14-day regimen of haloperidol
caused an upregulation of dorsal striatal D2-like receptors (Bmax = 153%
increase), while the same regimen of aripiprazole produced only a slight,
nonsignificant increase in the density of D2-like receptors (Bmax = 126%
increase). As with the Inoue et al. (1997) study, the Bmax values of aripiprazole
and vehicle control groups did not differ. In conclusion, repeated treatment with
haloperidol increases the number of dorsal striatal D2-like receptors, but the
impact of repeated aripiprazole treatment on these receptors remains elusive.
Alterations in the Percentage of D2High Receptors
A separate issue is whether repeated treatment with dopamine
antagonists alters the affinity state of D2-like receptors. This issue is particularly
important because aripiprazole appears to exert antagonistic effects when D2like receptors are in a state of high affinity. In a critical study for this thesis,
Seeman (2008) reported that repeated treatment with aripiprazole caused a
significant increase in the percentage of dorsal striatal D2High receptors. Not
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surprisingly, chronic treatment with haloperidol also results in an elevated
percentage of D2High receptors (Seeman et al., 2005).
In summary, repeated treatment with haloperidol causes a dramatic
upregulation of D2-like receptors, whereas the effect of repeated aripiprazole
treatment on D2-like receptor numbers is ambiguous (Inoue et al., 1997;
Tadokoro et al., 2012). In contrast, repeated treatment with both haloperidol and
aripiprazole increases the percentage of D2-like receptors in a high affinity state.
If anything, aripiprazole may increase D2High receptors to a greater extent than
haloperidol (Seeman et al., 2005); this suggests that repeated aripiprazole
treatment may cause long-term modifications in behavior by altering D2 affinity
as opposed to upregulating D2-like receptors.
Changes in D2 Receptor cAMP and Akt Signaling Pathways
Repeated treatment with haloperidol and aripiprazole affects the cAMP
and Akt signaling pathways. As mentioned in a previous chapter, D2-like receptor
stimulation activates a Gi protein which decreases adenylyl cyclase activity and,
as a consequence, reduces cAMP levels and PKA activity (Beaulieu &
Gainetdinov, 2011; Kebabian & Cote, 1981; Missale et al., 1998). The Akt
pathway is also modulated by D2-like receptor stimulation. Specifically, D2-like
receptor activation decreases Akt levels and inhibits GSK-3β activity which, in
turn, inhibits β-catenin (Freyberg, Ferrando, & Javitch, 2010; Li & Gao, 2011).
Importantly, GSK-3β is a critical component regulating hyperdopaminergic
behaviors, since decreased activity in this pathway is associated with
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hyperdopaminergic conditions (Li & Gao, 2011; Li, Xi, Roman, Huang, & Gao,
2009).
D2-like receptor blockade increases activity within the cAMP pathway. For
example, chronic treatment with haloperidol increases adenylyl cyclase activity
(Iwatsubo & Clouet, 1975). In vitro studies show a pronounced increase in cAMP
following exposure to haloperidol, and lesser increases in cAMP levels after
treatment with second-generation antipsychotics (Masri et al., 2008). Curiously,
aripiprazole decreases cAMP levels in vitro (Masri et al., 2008). Chronic
treatment with haloperidol increases PKA activity in the dorsal striatum, while
other evidence suggests that acute haloperidol treatment may also result in
phosphorylation of PKA (Pan, Chen, Lian, Huang, & Deng, 2015; Turalba, LeiteMorris, & Kaplan, 2004). Acute treatment with aripiprazole did not produce a
significant change in the amount of phosphorylated PKA (Pan et al., 2015).
The Akt pathway is also affected by repeated treatment with dopaminergic
compounds (Alimohamad, Rajakumar, Seah, & Rushlow, 2005). For example, a
long-term regimen of haloperidol significantly increased phosphorylated Akt
levels in the dorsal striatum of both rats and mice (Emamian, Hall, Birnbaum,
Karayiorgou, & Gogos, 2004; Sutton & Rushlow, 2011); however, the acute
effects of haloperidol treatment on phosphorylated Akt remain unclear, since
there are conflicting reports that haloperidol either increases phosphorylated Akt
levels (Emamian et al., 2004) or has no effect (Pan et al., 2015). Acute
aripiprazole treatment had somewhat different actions, as acute treatment with
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aripiprazole produced only a nonsignificant increase in phosphorylated Akt levels
(Pan et al., 2015).
Other proteins within the Akt pathway are also altered after treatment with
antipsychotics. Repeated treatment with a moderate dose of haloperidol
increased both GSK-3β and β-catenin levels in dorsal striatal tissue (Alimohamad
et al., 2005). Within the dorsal striatum, increased GSK-3β labeling was
observed in cell bodies and nearby dendrites, whereas increased β-catenin
labeling occurred more densely in nuclear or neuropil areas. Elevated levels of
GSK-3β and β-catenin were also found in deeper layers of the prefrontal cortex,
which coincides with the location of D2-like receptors (Alimohamad et al., 2005;
Berendse, Galis-de Graaf, & Groenewegen, 1992; Larson & Ariano, 1995). Acute
haloperidol treatment did not alter GSK-3β or β-catenin levels (Pan et al., 2015);
however, a single injection of aripiprazole did increase phosphorylated GSK-3β
(Pan et al., 2015).
In summary, these results indicate that repeated treatment with
haloperidol or aripiprazole affects the cAMP and Akt signaling pathways of adult
rats, although the effects of haloperidol are generally more pronounced.
Regarding the cAMP pathway, both acute and repeated treatment with
haloperidol increased PKA catalytic activity (Dwivedi et al., 2002; Pan et al.,
2015). There is a lack of evidence regarding the effects of repeated aripiprazole
treatment on phosphorylated PKA, but acute aripiprazole did increase the alpha
PKA catalytic subunit with no significant increase in the ratio of p-PKA to PKA
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(Pan et al., 2015). Within the Akt pathway, repeated haloperidol treatment lead to
increases in phosphorylated Akt, GSK-3β, and β-catenin (Alimohamad et al.,
2005; Emamian et al., 2004; Sutton & Rushlow, 2011). In acute models, there is
conflicting evidence regarding the effects of haloperidol on phosphorylated Akt
levels, but studies consistently find that haloperidol does not increase the amount
of phosphorylated GSK-3β (Emamian et al., 2004; Pan et al., 2015; Sutton &
Rushlow, 2011). On the other hand, the effects of repeated aripiprazole
treatment on the Akt pathway are unknown. That being said, acute aripiprazole
administration did increase the amount of phosphorylated GSK-3β and, perhaps,
phosphorylated Akt (Pan et al., 2015).

Effects of Repeated Treatment of Haloperidol and Aripiprazole on D2-like
Receptors in the Dorsal Striatum of Young Rodents
Repeated treatment with haloperidol and aripiprazole in young rats causes
upregulation of D2-like receptors in the dorsal striatum (Der-Ghazarian,
Charntikov, Varela, Crawford, McDougall, 2010). Similar to adult rodents,
haloperidol appears to produce greater D2-like receptor upregulation than
aripiprazole (Der-Ghazarian et al., 2010). To date, no studies have investigated
the acute or chronic effects of haloperidol or aripiprazole on the cAMP or Akt
second messenger systems of young rats.
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CHAPTER SIX
THESIS STATEMENT

Conclusion
Despite the effectiveness of first-generation antipsychotics in reducing
positive symptoms, extrapyramidal side effects remain a major problem when
treating schizophrenia. Therefore, there is a need for an effective
pharmacotherapy with fewer side effects, such as aripiprazole. The ability of
repeated aripiprazole treatment to mitigate psychosis has been demonstrated,
although relatively little is known about its mechanism of action. Aripiprazole is
frequently prescribed to children and adolescents because of its low side effect
profile (Kirino, 2012; Masi et al., 2009; Stachnik & Nunn-Thompson, 2007; Yoo et
al., 2011); however, few preclinical studies have examined the neural effects of
aripiprazole in young populations. For this reason, more information is needed
regarding the effects of repeated aripiprazole treatment across ontogeny.
Alterations in D2-like receptor functioning are responsible for many of the
symptoms associated with schizophrenia as well as the extrapyramidal side
effects that result from dopamine antagonist treatment. For example, D2-like
agonists induce psychosis and exacerbate psychotic symptoms, whereas D2-like
receptor antagonists reduce positive symptoms (Li & Gao, 2011; Lieberman et
al., 1987). In terms of side effects, D2-like agonists alleviate Parkinsonism and
related motoric disturbances (Li & Gao, 2011). Many years ago, Davis et al.
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(1991) proposed that schizophrenia is primarily due to dysregulation of dopamine
systems in the nucleus accumbens and prefrontal cortex. More recently, Seeman
(2011) has extended this model by proposing that an excess of D2High receptors
is responsible for psychosis. Although research examining the effects of
antipsychotic drugs on the D2High receptors of adult rats is well along (Seeman,
2008), it is important to determine the effects of repeated haloperidol and
aripiprazole treatment on the percentage of D2High receptors in young rats.
Traditionally, it is understood that repeated treatment with first-generation
antipsychotics lessens psychosis through antagonism of D2-like receptors, which
has the unwanted side effect of upregulating these receptors. Despite symptom
reduction, first-generation antipsychotics cause more extrapyramidal side effects
than second- or third-generation antipsychotics (Croxtall, 2012; Leucht et al.,
2009). As an example, repeated treatment with haloperidol results in an
upregulation of D2-like receptors, a larger percentage of D2High receptors, and
behavioral supersensitivity (Inoue et al., 1997; Seeman et al., 2005; Tadokoro et
al., 2012; Varela et al., 2014). In contrast, treatment with the third-generation
antipsychotic aripiprazole results in a slight, nonsignificant upregulation of D2-like
receptors, an increased percentage of D2High receptors, and relatively less
supersensitivity (Seeman, 2008; Tadokoro et al., 2012; Varela et al., 2014). The
lack of pronounced D2-like receptor upregulation suggests that aripiprazole does
not operate under the traditionally understood mechanisms of first-generation
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antipsychotics, although both haloperidol and aripiprazole do increase the
percentage of D2High receptors (Seeman, 2008).
Since dopamine system dysfunction is a hallmark of schizophrenia, it is
not surprising that second messenger systems associated with D2-like receptors
are often dysregulated in schizophrenia. Indeed, some researchers speculate
that dysfunction involving the cAMP and Akt pathways may be a critical neural
mechanism underlying schizophrenia (Beaulieu, Del’Guidice, Sotnikova,
Lemasson, & Gainetdinov, 2011; Emamian et al., 2004; Karam et al., 2010;
Lovestone, Killick, Di Forti, & Murray, 2007). For example, Li et al. (2009) have
hypothesized that GSK-3β, a component of the Akt pathway, may modulate
dopamine-dependent behaviors by inhibiting NMDA receptors in the prefrontal
cortex. Thus, hyperdopaminergic behaviors may be a consequence of GSK-3β
attenuating glutamatergic functioning (Li et al., 2009). Regardless of the exact
explanation, it is clear that PKA, Akt, and GSK-3β are dysregulated in the frontal
cortex of schizophrenics (Emamian et al., 2004).
Consistent with the latter findings, repeated and acute treatment with
antipsychotic drugs alters the functioning of the cAMP and Akt pathways. Within
the dorsal striatum of adult rats, repeated haloperidol treatment increases
phosphorylated PKA, Akt, GSK-3β, and β-catenin (Alimohamad et al., 2005;
Dwivedi et al., 2002; Emamian et al., 2004; Sutton & Rushlow, 2011). In contrast,
there is a general lack of information regarding the effects of repeated
aripiprazole treatment on the cAMP and Akt pathways. The only available
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evidence suggests that acute treatment with aripiprazole slightly enhances the
phosphorylation of GSK-3β and possibly Akt (Pan et al., 2015).
In addition to possibly being involved in the manifestation of
schizophrenia, alterations of the cAMP and Akt pathways may be responsible for
some of the side effects (e.g. extrapyramidal effects) associated with
antipsychotic drugs. In other words, D2-like receptor antagonists may produce
side effects by causing persistent change in the cAMP and/or Akt second
messenger systems through actions at D2-like receptors. Based on the evidence
presented above, it is possible that aripiprazole has a lesser impact on these
second messenger systems, thereby resulting in fewer side effects. Consistent
with this idea, repeated aripiprazole treatment causes relatively less behavioral
supersensitivity in young rats than does haloperidol (Varela et al., 2014).
This thesis examined the effects of repeated aripiprazole and haloperidol
treatment on dopamine systems in the dorsal striatum of preadolescent and adult
rats. We previously reported that repeated haloperidol and aripiprazole
treatment increased the percentage of D2High receptors in young rats; however,
we did not assess whether these changes had any functional consequence.
Therefore, I examined the functionality of D2-like receptors by conducting GTPγS
assays and measuring the cAMP and Akt second messenger systems, after
repeated exposure to haloperidol or aripiprazole. My expectation was that
aripiprazole and haloperidol would increase the efficacy of D2-like receptors as
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measured by the GTPγS assay. These D2-like receptor changes, in turn, were
predicted to cause enhanced responsiveness in the cAMP and Akt pathways.

Proposed Hypotheses
In my first experiment, [35S]GTPγS binding assays were conducted to
assess the effects of repeated haloperidol and aripiprazole treatment on the
efficacy of D2-like receptors (i.e. the coupling of Giα to D2 receptors).
Preadolescent and adult rats were pretreated with haloperidol or aripiprazole for
11 consecutive days. After either a 4 or 8 day drug abstinence period, rats were
euthanized and dorsal striatal tissue dissected out and stored until assay. Based
on the previously gathered D2High data, I hypothesized that the D2-like receptors
of younger rats would show a greater efficacy than adult rats. I did not expect
that the different drug abstinence periods would affect GTPγS binding. I also
hypothesized that the D2-like receptors of haloperidol-treated rats would display
greater efficacy than aripiprazole-treated groups, and that D2-like receptors of
both drug groups would demonstrate greater efficacy than those treated with
saline.
In my second experiment, I assessed the cAMP second messenger
system. More specifically, I measured PKA subunits (i.e. alpha and beta catalytic
subunits, regulatory subunits, and phosphorylated PKA) in order to determine if
upregulation of any of these subunits occurred after repeated haloperidol or
aripiprazole treatment. Preadolescent and adult rats were repeatedly
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administered haloperidol, aripiprazole, or vehicle for 11 days, and dorsal striatal
tissue was extracted after a 4 or 8 day drug abstinence period. Levels of PKA
subunits in the dorsal striatum was measured using Western Blot analysis. I
hypothesized that there would be greater increases in the amount of
phosphorylated PKA in younger rats compared to adult rats, but no differences
due to the 4 or 8 day drug abstinence periods. Additionally, I hypothesized that
there would be increased phosphorylated PKA in haloperidol-treated rats in
comparison to aripiprazole-treated rats, and that both haloperidol and
aripiprazole would induce elevated levels of phosphorylated PKA when
compared to rats that receive vehicle.
I also assessed components of the Akt pathway, specifically, the amount
of phosphorylated Akt relative to nonphosphorylated Akt, and the amount of
phosphorylated GSK-3β relative to nonphosphorylated GSK-3β. As mentioned
previously, preadolescent and adult rats received repeated injections of
haloperidol, aripiprazole, or vehicle for 11 days. Dorsal striatal tissue was
extracted after a 4 or 8 day drug abstinence period and phosphorylated Akt and
GSK-3β was measured using Western Blot analysis. I hypothesized that younger
rats would demonstrate larger increases in phosphorylated Akt and GSK-3β
levels than adult rats, and that there would be no differences between the 4 or 8
day drug abstinence periods. I also hypothesized that rats treated with
haloperidol and aripiprazole would display elevated amounts of phosphorylated
Akt and GSK-3β relative to rats that receive vehicle.
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CHAPTER SEVEN
METHODS

Subjects
Subjects were 164 male and female Sprague-Dawley rats (Charles River
Laboratories, Hollister, CA, USA). Eighty subjects were preadolescent rats born
and raised at California State University, San Bernardino (CSUSB).
Preadolescent rats were culled to 10 pups per litter by PD3 and housed with the
dam in the same cage. Eighty-four adult subjects were purchased from Charles
River Laboratories and arrived on PD51-59. Approximately equal numbers of
male and female rats were assigned to all conditions.
The colony room was maintained at a temperature of 22-24°C and was
kept under a 12 hour light/dark cycle. Drug administration was conducted during
the light cycle. Food and water were available at all times. All subjects were
treated according to the “Guide for the Care and Use of Mammals in
Neuroscience and Behavioral Research” (National Research Council, 2003) and
the research protocol was approved by the Institutional Animal Care and Use
Committee at CSUSB.

Drugs
Haloperidol was dissolved in saline, whereas aripiprazole was dissolved in
(2-hydropropyl)-β-cyclodextrin (HBC) solution. Saline served as the control
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vehicle for haloperidol, and HBC served as the control vehicle for aripiprazole.
Drugs were injected at a volume of 2.5 ml/kg for preadolescent rats and 2 ml/kg
for adults.

Design
These experiments used 2 x 2 x 3 between-subjects experimental designs
(Subject Age: young vs. adult; Drug Type: haloperidol vs. aripiprazole vs.
saline/HBC; Drug Abstinence Period: 4 or 8 days). A drug abstinence period of
either 4 or 8 days was chosen because these durations are commonly used for
adult rats, although there is a dearth of evidence regarding an ideal drug
abstinence period for young rats. Similar drug abstinence periods were used to
assess the effects of repeated aripiprazole and haloperidol treatment on the
dorsal striatum of early adolescent rats (Varela et al., 2014).
D2 receptor function was measured using GTPγS assays and Western
Blots. Specifically, the GTPγS assay measured the coupling of Giα to D2
receptors and the Western Blots assessed Akt, GSK-3β, and PKA subunit levels.
Male and female rats were included in the study, with sex differences analyzed
separately from the previously mentioned statistical analyses.
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Procedures
Pretreatment Phase
Young rats began injections at PD10, while adult rats began injections at
PD80. Haloperidol (1 mg/kg), aripiprazole (10 mg/kg), and vehicle (saline/HBC),
were administered for 11 days: postnatal day PD10 through PD20 for young rats
and PD70 through PD80 for adult rats. Injections were followed by a drug
abstinence period of either 4 or 8 days. Subjects were then sacrificed by rapid
decapitation (PD24 or PD28 for juveniles and PD84 or PD88 for adults). Dorsal
striatal tissue was dissected out and kept at -80 °C until assay.
[S35]GTPyS Binding Assay
On the day of assay, tissue was thawed and homogenized in 100 volumes
of 50 mM Tris–HCl buffer (pH 7.4) for approximately 20 s using a Brinkman
Polytron. Homogenates were centrifuged at 20 000 × g for 30 min. The pellet was
then resuspended in 100 volumes of the same buffer and centrifuged again at 20
000 × g for 30 min. The final pellet was suspended in approximately 20 volumes
of buffer (pH 7.4) and incubated for 30 min at 37 °C to remove endogenous
transmitter.
[35S]GTPγS binding was conducted in duplicate tubes in assay buffer (50
mM Tris–HCl, 120 mM NaCl) containing 30 μM GDP, 10–20 μg protein, and
dopamine in various concentrations. Nonspecific binding was determined in the
presence of 30 μM cold GTPγS. The tubes were preincubated for 15 min at 37
°C, after which 0.1 nM [35S]GTPγS were added. Following the addition of
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[35S]GTPγS, tubes were incubated for an additional 45 min at 37 °C. The
incubation period was terminated by filtering the contents of the tubes using
glass fiber filters. Net agonist-stimulated [35S]GTPγS binding values were
calculated by subtracting basal binding values (without agonist) from agoniststimulated values (with agonist) and dividing by basal values. Agonist potency
(pEC50) and agonist efficacy (Emax) were determined by iterative nonlinear
regression fitting using Prism (Graph Pad Software).
Western Blot Analyses for PKA and Akt
The levels of Akt/p-Akt, GSK-3β/p-GSK-3β, and PKA/p-PKA were
determined using Western Blotting. Four different proteins were used to assess
PKA: the alpha catalytic subunit (PKA-Cα), the beta catalytic subunit (PKA-Cβ),
the regulatory subunit (PKA-RII), and p-PKA. Briefly, dorsal striatal samples
(20 µg protein) were mixed with lamemmeli buffer, boiled for 5 min at 95 °C, and
loaded on 12% polyacrylamide gels. Homogenates were then transferred to
polyvinylidene fluoride (PVDF) membranes. Membranes were rinsed in TBST
buffer (20 mM Tris-HCl, 150 mM NaCl, and 0.5% Tween20) and then blocked
with 5% non-fat milk in TBST (diluted in blotto) for 2 h. Membranes were then
incubated with the primary rabbit antibody for Akt [1:20,000 (diluted in blotto);
#C67E7], phospho-Akt [Thr308; 1:10,0000 (diluted in blotto); Cell Signaling
Technology, #D25E6], PKA-Cβ [1:10,000 (diluted in blotto); Santa Cruz
Biotechnology, #SC-904], or p-PKA [Thr197; 1:50,000 (diluted in blotto); Cell
Signaling Technology, #5661] overnight at 4 C. The next day, the blots were
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washed five times with TBST for 5 min each and then incubated in anti-rabbit
IgG-HRP secondary antibody [1:50,000 (diluted in blotto); Santa Cruz
Biotechnology] 2 h at room temperature. After membranes were washed five
times in TBST, immunoreactive proteins were revealed with enhanced
chemiluminescence (Thermo Fisher SuperSignal West Dura Extended Duration
Substrate, Thermo Fisher Scientific). Immunoreactive bands were then visualized
and quantified using a computer-assisted digital imagining program (Chemi-Doc,
Bio-Rad). Following quantification, blots were mildly striped with a commercially
available buffer (Restore Western Blot Stripping Buffer, Thermo Fisher
Scientific), and the blotting procedure was redone using primary rabbit antibodies
for GSK-3 α/β [1:20,000 (diluted in blotto); Cell Signaling, #D75D3], phosphoGSK-3β [Ser9; 1:20,000 (diluted in blotto); Cell Signaling Technology, #D3A4],
PKA-RII [1:10,000 (diluted in blotto); Santa Cruz Biotechnology, #SC-908], and
PKA-Cα [1:75,000 (diluted in blotto); Cell Signaling Technology, #5842].

Data Analyses
Data were initially analyzed using four-way ANOVAs (Age x Drug x
Abstinence Period x Sex) for the GTPγS and Western Blot experiments. Sex was
excluded as a factor in the final statistical analyses if the main effect and
interactions involving the sex independent variable were nonsignificant. Tukey
tests (p<.05) were used for making planned and post hoc comparisons. Litter
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effects were controlled by assigning no more than one subject from each litter to
a particular group (for a fuller discussion of litter effects, see Zorrilla, 1997).
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CHAPTER EIGHT
RESULTS

Experiment 1
GTPγS Binding
Repeated treatment with haloperidol or aripiprazole did not significantly
affect D2-like receptor efficacy (i.e. Emax values) in young or adult rats (see Table
1) [Drug x Age interaction, F(2,60) = .68, p = .51]. Likewise, neither haloperidol or
aripiprazole altered the potency (i.e. pEC50 values) of NPA-stimulated
[35S]GTPγS specific binding in either age group [Drug x Age interaction, F(2,60)
= 1.43, p = .25]. D2 receptor efficacy and potency were not differentially affected
by the drug abstinence period [F(1,60) = .34, p = .56; F(1,60) = .044, p = .835].
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Table 1. Mean D2 Receptor Efficacy and Potency (Emax and pEC50, respectively)
in the Dorsal Striatum of Young (PD24 and PD28) and Adult (PD84 and PD88)
Rats.
Drug
Emax
pEC50
Young

Adult

Young

Adult

27.08 (+3.89)

32.96 (+4.27)

6.35 (+0.26)

6.23 (+0.31)

Aripiprazole 20.61 (+2.66)

30.15 (+3.02)

7.14 (+0.30)

6.47 (+0.32)

Haloperidol

28.92 (+3.75)

6.46 (+0.29)

6.78 (+0.23)

Vehicle

27.17 (+2.47)

Note: Emax (mean, +SEM) is expressed as fmol/mg weight wet tissue; pEC50
(mean, +SEM) is the log of EC50 (nm)
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Experiment 2
Western Blots
In both age groups, haloperidol significantly increased the expression of
dorsal striatal PKA-Cα (122.82% ± 7.2), PKA-Cβ (115.98% ± 5.6), and PKA-RII
(122.30% ± 6.3), but not p-PKA (see Tables 2 and 3) [Drug main effect, F(2,84) =
5.30, p = 0.007; F(2,84) = 5.04, p = 0.009; and F(2,84) = 6.08, p = 0.003,
respectively]. Haloperidol also significantly increased PKA-Cβ and PKA-RII levels
relative to aripiprazole (96.87% ± 5.1 and 105.26% ± 5.4, respectively). After 4
abstinence days, PKA-Cα and PKA-RII levels were higher in young rats than
adult rats (see Figures 1 and 2) [Age x Drug Abstinence Period interaction,
F(1,84) = 6.15, p = .015; and F(1,84) = 7.25, p = .009, respectively]. Adult rats
had higher levels of both proteins when assessed after 8 rather than 4
abstinence days. No significant main effects or interactions involving the sex
independent variable were apparent.
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Table 2. Mean Dorsal Striatal PKA-Cα and PKA-Cβ Values of Young (PD24 and
PD28) and Adult (PD84 and PD88) Rats.
Drug
PKA-Cα
PKA-Cβ
Young

Adult

Young

Adult

100

100

100

100

Aripiprazole 120.26 (+8.9)

110.33 (+6.1)

99.98 (+8.0)

93.75 (+6.6)

Haloperidol

118.12 (+8.4)*

119.07 (+8.1)*†

112.89 (+8.0)* †

Vehicle

127.52 (+11.9)*

Note: PKA-Cα and PKA-Cβ values (mean, +SEM) are expressed as percent of
same-aged vehicle controls.
*Significantly different from rats administered vehicle (saline/HBC)
†Significantly different from rats administered aripiprazole
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Table 3. Mean Dorsal Striatal PKA-RII and p-PKA values of Young (PD24 and
PD28) and Adult (PD84 and PD88) Rats.
Drug
PKA-RII
p-PKA

Vehicle

Young

Adult

Young

Adult

100

100

100

100

102.52 (+8.4)

121.06 (+11.5) 106.75 (+8.2)

121.97 (+9.4)* †

116.13 (+9.1)

Aripiprazole 107.99 (+7.2)

Haloperidol

122.64 (+8.6)* †

116.78 (+11.6)

Note: PKA-RII and p-PKA values (mean, +SEM) are expressed as percent of
same-aged vehicle controls.
*Significantly different from rats administered vehicle (saline/HBC)
†Significantly different from rats administered aripiprazole
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*†

Figure 1. Mean percent (+SEM) PKA-Cα levels of young and adult rats after four
or eight drug abstinence days.
*Significantly different from adult rats tested after 8 abstinence days
†Significantly different from young rats tested after 4 abstinence days
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*†

Figure 2. Mean percent (+SEM) PKA-RII levels of young and adult rats after four
or eight drug abstinence days.
*Significantly different from adult rats tested after 8 abstinence days
†Significantly different from young rats tested after 4 abstinence days
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Repeated administration of haloperidol significantly increased p-GSK-3β
levels in the dorsal striatum of young and adult rats (see Table 4) [Drug main
effect, F(2,84) = 4.96, p = .009], but neither haloperidol nor aripiprazole
significantly affected GSK-3β, Akt, or p-Akt levels (see Tables 4 and 5). A
significant Age x Drug Abstinence Period interaction was found [F(1,84) = 6.90, p
= .01], as Akt levels were elevated in PD24 rats when compared to PD84 rats
(see Figure 3). Among adult rats, Akt levels were greater after 8 abstinence days
than at 4 days. No significant main effects or interactions involving the sex
independent variable were apparent.
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Table 4. Mean Dorsal Striatal GSK-3β and p-GSK-3β Values of Young (PD24
and PD28) and Adult (PD84 and PD88) Rats.
Drug
GSK-3β
p-GSK-3β

Vehicle

Young

Adult

Young

Adult

100

100

100

100

Aripiprazole 102.09 (+11.0)

119.86 (+19.0) 90.35 (+10.6)

Haloperidol

109.61 (+11.0) 148.12 (+25.6)* 140.00 (+16.8)*

128.11 (+11.1)

134.19 (+15.4)

Note: GSK-3β and p-GSK-3β values (mean, +SEM) are expressed as percent of
same-aged vehicle controls.
*Significantly different from rats administered vehicle (saline/HBC)

56

Table 5. Mean Dorsal Striatal Akt and p-Akt Values of Young (PD24 and PD28)
and Adult (PD84 and PD88) Rats.
Drug
Akt
p-Akt
Young

Adult

Young

Adult

100

100

100

100

Aripiprazole 105.04 (+5.8) 108.97 (+8.7)

119.2 (+14.2)

135.21 (+19.6)

Haloperidol

140.69 (+19.8)

123.65 (+15.9)

Vehicle

108.74 (+4.9) 100.88 (+8.6)

Note: Akt and p-Akt values (mean, +SEM) are expressed as percent of sameaged vehicle controls.
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*†

Figure 3. Mean percent (+SEM) Akt levels of young and adult rats after four or
eight drug abstinence days.
*Significantly different from adult rats tested after 8 abstinence days
†Significantly different from young rats tested after 4 abstinence days
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CHAPTER NINE
DISCUSSION

Schizophrenia is a disorder that can affect humans across the life-span,
and a variety of factors are thought to initiate its onset throughout maturation.
Although first-, second-, and third-generation antipsychotics reduce positive
symptoms, this is often at the cost of persisting extrapyramidal effects (Croxtall,
2012; Leucht et al., 2009; Mailman & Murthy, 2010). These undesirable effects
are likely the result of an excessive number of D2 receptors in the dorsal striatum
(Inoue et al., 1997; Schröder, Bubeck, & Sauer, 2000, Silvestri et al., 2000;
Varela et al., 2014). Consistent with this explanation, repeated treatment with
haloperidol and aripiprazole causes long-term increases in dorsal striatal D2High
receptors in young rats, as well as adults (Seeman, 2008). Importantly, the
ramifications of these receptor changes on D2 second messenger systems have
not previously been determined. Specifically, it is unclear whether drug-induced
changes in the percentage of D2High receptors affect the functioning of
downstream signaling pathways. In an effort to examine this idea, I sought to
determine whether repeated haloperidol or aripiprazole treatment would alter the
efficacy of D2 receptors and/or impact the cAMP and Akt signaling pathways.
Both young and adult rats were included in this study since (1) haloperidol and
aripiprazole are commonly prescribed to humans across ontogeny, and (2) young
rats possess a higher percentage of D2High receptors than adults.
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Development has emerged as an important factor when assessing D2
receptor function. Dorsal striatal D2 receptors appear to function differently
across development, as young rats possess a greater percentage of D2 High
receptors than adolescent or adult rats (McDougall et al., 2015). Because of this
finding, the current study focused on the effects of chronic aripiprazole treatment
on the dorsal striatum during development. For example, we previously
demonstrated an increase in the percentage of D2High receptors in the dorsal
striatum of young rats following repeated haloperidol and aripiprazole treatment.
Whether these receptor changes have functional implications is unknown. To
assess functionality, I measured the long-term effects of haloperidol and
aripiprazole on GTPγS binding, as well as D2 signaling mechanisms.

Effects of Repeated Haloperidol and Aripiprazole Treatment on D2 Receptor
Efficacy and Potency
The GTPγS assay is used to determine the efficacy or functionality of D2
receptors (Harrison & Traynor, 2003; Milligan, 2003). Because young rats have a
greater percentage of D2High receptors than adults (McDougall et al., 2015), I
hypothesized that the D2 receptors of young rats, when compared to adults,
would have greater efficacy. Following either a 4- or 8-day drug abstinence
period, haloperidol-treated rats were predicted to display more efficacious
receptors than aripiprazole-treated rats, while rats in both treatment groups were
predicted to show enhanced D2 receptor efficacy relative to control rats. In
contrast to original expectations, D2 receptor efficacy did not significantly change
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following repeated haloperidol or aripiprazole treatment. In fact, D2 receptor
efficacy did not differ between young and adult rats, drug groups, drug
abstinence periods, nor sexes. Likewise, potency (pEC50) did not differ according
to age, drug, abstinence period, or sex. These results are contrary to original
expectations. One possibility is that drug-induced increases in the percentage of
D2High receptors are independent of changes in D2 receptor efficacy.
Alternatively, D2 receptors in the high affinity state may not initiate changes in
the cAMP system through traditionally understood mechanisms (i.e. the
dissociation of Giα from the βγ complex). This possibility suggests that the effects
of increased D2High receptors are independent of the activation of the cAMP
signaling cascade. Thus, PKA subunits may upregulate independently of
changes in D2/Gia coupling, and alternate D2 receptor signaling pathways may
be responsible for changes in the cAMP system.

Effects of Repeated Haloperidol and Aripiprazole Treatment on the cAMP
Pathway
Although haloperidol and aripiprazole did not alter the dissociation of Gia
from the βy complex, it remains possible that alterations in the percentage of
D2High receptors might affect downstream proteins within the cAMP pathway. I
previously hypothesized that young rats would display greater increases in pPKA relative to adult rats, and that haloperidol treatment would lead to greater
elevations of p-PKA than aripiprazole. Interestingly, repeated haloperidol
treatment did not alter p-PKA, but it did increase the amount of PKA-Cα, PKA61

Cβ, and PKA-RII relative to vehicle controls. The PKA-Cβ and PKA-RII levels of
haloperidol-treated rats were also significantly greater than the aripiprazoletreated groups. No differences were found between age groups, sex, nor drug
abstinence period. The increases in PKA subunits may be attributed to the
general upregulation of D2 receptors after repeated haloperidol treatment.
Interestingly, since haloperidol and aripiprazole both increase the percentage of
D2High receptors, it is likely that this factor cannot solely account for the changes
in the cAMP pathway after haloperidol treatment. On the contrary, since D2
receptors do not cause long-term changes in the quantity of PKA subunits after
aripiprazole treatment, perhaps the unique actions of aripiprazole as a partial
agonist allow for an increase in D2High receptors without lasting effects on the
cAMP pathway. This pattern of results preserves the possibility that increased
levels of PKA are linked to some of the more lasting actions of haloperidol, such
as extrapyramidal effects.
Using a different model, Pan and colleagues have attempted to determine
the short-term effects of haloperidol and aripiprazole treatment on PKA subunits.
However, a critical distinction must be made in comparing the methods of Pan et
al. (2015, 2016a, 2016b) to the present study. Notably, the work of Pan et al.
(2015, 2016a, 2016b) assessed the short-term effects of haloperidol and
aripiprazole treatment on second messenger components, while this thesis
focused on the long-term effects of these drugs on D2 second messenger
systems after 4- or 8-day drug abstinence period. Thereby, the interpretation of
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Pan et al. (2015, 2016a, 2016b) is centered on the effects of haloperidol and
aripiprazole shortly after the conclusion of drug treatment; whereas, the current
study is concerned with long-term, potentially permanent changes in receptor
function after repeated drug treatment. Pan et al. (2015, 2016b) reported
increased levels of PKA-Cα after both a 1- and 7-day haloperidol and aripiprazole
treatment regimen. p-PKA was also increased after a 7-day regimen of
haloperidol but not aripiprazole (Pan et al., 2016b). Though this evidence
suggests that aripiprazole exerts less intense effects on the cAMP system when
compared to haloperidol, the present results also highlight the importance of the
drug abstinence period when considering the effects of drug-induced receptor
changes on the cAMP system.
The current study demonstrated increases in PKA subunits after repeated
haloperidol treatment, which was unlike effects occurring after aripiprazole
treatment. Specifically, upregulation of PKA subunits (i.e., PKA-Cα, PKA-Cβ, and
PKA-RII) was present 4 and 8 days after cessation of repeated haloperidol
treatment, whereas upregulation of the PKA system was not apparent following
repeated aripiprazole treatment. In terms of haloperidol, it is likely that the
increase in regulatory subunits (PKA-RII) was in direct response to increases in
catalytic activity. This effect was not observed when using an acute treatment
model, as Pan et al. (2015) reported decreased PKA-RII levels after a single
injection of haloperidol. It is clear that both haloperidol and aripiprazole cause
acute, short-term activation of the cAMP system (Pan et al., 2015); whereas, the
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present thesis indicates that haloperidol has more long-lasting effects on the
cAMP system than aripiprazole. One possibility is that the antagonistic actions of
haloperidol are more pronounced than those of aripiprazole, thus causing more
long-term effects. It is also possible that the partial agonist properties of
aripiprazole “soften” its upregulation of the cAMP system following the conclusion
of treatment. The lack of phosphorylation observed in the current study may also
provide insight about the long-term changes in the cAMP system after
haloperidol and aripiprazole treatment. Interestingly, the lack of p-PKA observed
in our chronic model could actually indicate increased PKA activity, since
phosphorylation of PKA can mute some activity of the kinase (Yu et al., 2013).
Regardless, the present results are consistent with the idea that some of the
behavioral differences observed after repeated haloperidol and aripiprazole
treatment may be due to upregulation in the cAMP system.

Effects of Repeated Haloperidol and Aripiprazole Treatment on the Akt Pathway
As previously mentioned, the Akt pathway may also play a critical role in
the therapeutic effects of aripiprazole, and the activity of proteins in this pathway
may even explain its low side effect profile (Pan et al., 2015). Since increases in
p-GSK-3β have been demonstrated in a short-term model, in which dorsal striatal
tissue was assessed 24 hrs following repeated haloperidol treatment (Pan et al.,
2016a), I hypothesized that haloperidol would also increase the p-GSK-3β and pAkt levels of adult rats when measured 4 and 8 days after drug discontinuation.
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Young rats were hypothesized to exhibit an even greater increase in p-GSK-3β
and p-Akt. The present results showed that haloperidol increased the amount of
p-GSK-3β, but not p-Akt, in both age groups. Aripiprazole caused a somewhat
different pattern of effects, as the partial agonist did not alter p-GSK-3β nor p-Akt
in either young or adult rats. Similar to the cAMP pathway, haloperidol has a
lasting impact on the Akt pathway, whereas aripiprazole does not. The differential
actions of these two compounds on p-GSK-3β levels may be due to the partial
agonist actions of aripiprazole. It is noteworthy that haloperidol and aripiprazole
affect other neurotransmitter systems (e.g., serotonergic, adrenergic, GABAergic,
glutamatergic, etc.) to differing extents, so it is also possible that the generally
more muted effects of aripiprazole may be a consequence of complex interplay
of many neurotransmitter systems.
The present results show that long-term models, in which neural effects
are measured 4 or 8 days after drug discontinuation, produce a very different
pattern of effects than short-term models. For example, we found that p-GSK-3β
signaling was elevated both 4 and 8 days after cessation of a 10-day haloperidol
regimen. In contrast, after a 24 hr drug abstinence period, Pan et al. (2015)
reported increased p-GSK-3β levels after a single injection of aripiprazole but not
haloperidol. Additionally, there were no short-term increases in p-GSK-3β after a
7 day regimen of haloperidol or aripiprazole, but haloperidol did increase Akt
levels (Pan et al., 2016a). When considered together with the cAMP data, the
results of this thesis and Pan et al. (2015, 2016a, 2016b) indicate the importance
65

of treatment length and drug abstinence period when assessing the effects of
repeated haloperidol and aripiprazole treatment. Perhaps phosphorylation of
GSK-3β after aripiprazole treatment provides some beneficial effects, such as
reduced extrapyramidal effects, but post-treatment phosphorylation of GSK-3β
may lead to less desirable side effects. Regardless, the consequences of
haloperidol treatment on p-GSK-3β leave open the possibility that aripiprazole’s
more favorable side effect profile may be partly due to the differential actions of
these drugs on the Akt pathway.

Development and the cAMP and Akt Pathways
Given its favorable treatment outcomes among humans of various ages, it
was critical to assess the actions of aripiprazole on D2 receptor systems in both
young and adult rats. Somewhat surprisingly, the effects of repeated haloperidol
and aripiprazole treatment did not differ between age groups. This finding has
interesting implications, for it supports the idea that D2 receptors function
similarly regardless of age and, therefore, the potential consequences of drug
action at these receptors is more or less the same. Previous research has
demonstrated a progressive linear increase in dopamine receptor content from
prenatal ages through preadolescence, followed by an overabundance of
receptors during adolescence, and then a decline to adult levels (Andersen,
Thompson, Rutstein, Hostetter, & Teicher, 2000; Tarazi & Baldessarini, 2000;
Teicher, Andersen, & Hostetter, 1995. D2High receptors also vary according to
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age, with young rats having a greater percentage of the high affinity D2 receptors
than adolescent or adult rats (McDougall et al., 2015). Due to changes observed
in D2 receptor content and affinity state throughout development, it was plausible
to hypothesize that the effects of haloperidol and aripiprazole would differ
according to age. In terms of the Akt and cAMP pathways, at least, our
hypotheses concerning age-dependent differences were not supported by the
data.

Drug Abstinence Period
Drug abstinence period is an important factor to take into account when
assessing the long-term effects of dopaminergic drugs. If behavioral or neural
effects are measured shortly after DA antagonist treatment then acute drug
effects are being examined; however, if assessment occurs days or weeks after
drug discontinuation then the effects of receptor upregulation are often at issue.
Haloperidol causes profound D2 receptor upregulation in preweanling and adult
rats (Der-Ghazarian, Charntikov, Varela, Crawford, & McDougall, 2010; O’Dell et
al., 1990; Wilmot & Szczepanik, 1989); whereas, repeated aripiprazole treatment
causes upregulation of D2 receptors in young rats, and may cause slight, nonsignificant D2 receptor upregulation in adult rats (Inoue et al., 1997; Tadokoro et
al., 2012). Thus, differences in upregulation could be responsible for the more
pronounced actions of haloperidol, relative to aripiprazole, on the cAMP and Akt
pathways across both age groups. Such an explanation is consistent with the
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idea that upregulation of D2 receptors is responsible for the extrapyramidal
effects caused by first-generation antipsychotics (Creese & Snyder, 1980;
Klawans & Rubovitz, 1972; Tarsy & Baldessarini, 1977).
In the present study, there were relatively few differences observed
between the 4- and 8-day drug abstinence periods, but that is probably because
upregulation was apparent at both time points. Among the differences that were
observed, young rats, when compared to adult rats, had elevated levels of PKACα and PKA-RII than adults after 4 abstinence days. In terms of the Akt pathway,
PD24 rats had higher Akt levels when compared to PD84 rats. In adult rats, Akt
levels were greater after 8 abstinence days than at 4 days. These findings
suggest the possibility that adult cAMP and Akt systems display upregulation of
various proteins well after termination of antipsychotic treatment, and that the
extent of these changes may be somewhat more pronounced 8 days after drug
cessation. In this regard, it would be interesting to assess the effects of
haloperidol and aripiprazole on Akt and cAMP system functioning weeks and
months after drug discontinuation.

Clinical Relevance
Considering the clinical aspects of these findings, it has long been known
that first-generation antipsychotics cause more extrapyramidal effects than
second-generation antipsychotics (Croxtall, 2012; Leucht et al., 2009).
Aripiprazole, which is often referred to as a “third-generation” antipsychotic, also
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has a favorable side effect profile with few extrapyramidal effects (DeLeon et al.,
2003; Keck et al., 2004; Marder et al., 2003). The results of this thesis are
consistent with the idea that the long-term effects of haloperidol on the cAMP and
Akt pathways may underlie its adverse effects; whereas, the lack of persistent
change in cAMP and Akt pathways after aripiprazole treatment may be
responsible for its superior side effect profile. In regard to development,
haloperidol and aripiprazole likely exert their unique long-term effects
consistently across young and adult ages. With this in mind, these results reflect
the minimal side effects reported after aripiprazole treatment in adults as well as
children. With that being said, some studies have reported that aripiprazole
causes increased extrapyramidal effects in younger ages when compared to
second-generation antipsychotics (Amor, 2012; Doey, 2012; McKinney & Renk,
2011). Perhaps children display elevated extrapyramidal effects after aripiprazole
treatment because of increased D2 receptor upregulation that is independent of
actions on the cAMP and Akt systems.
In terms of limitations, one concern regarding the translational relevance
of this work is the dosage of aripiprazole (10 mg/kg/day) administered to rats,
which is much higher than typical human doses (10-30 mg/kg/day). However, the
different dosages were actually used to control elimination rate, which is much
faster in rats than humans (Greenaway & Elbe, 2009; Mallikaarjun, Salazar, &
Bramer, 2004; Shimokawa, Akiyama, Kashiyama, Koga, & Miyamoto, 2005).
Another concern is the length of the drug abstinence period used in rats when
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compared to the much longer abstinence periods experienced by humans.
Although these time factors are difficult to compare, the drug abstinence periods
used in this study likely map to human brain development and aging over months
or years (Varela et al., 2014).

Conclusion
Overall, the results of this thesis indicate that aripiprazole has different
long-term effects on D2 receptor signaling pathways than haloperidol.
Aripiprazole has less extreme or prolonged effects on D2 receptor signaling
pathways, as evidenced by the lack of post-treatment upregulation in cAMP and
Akt pathways. These results are consistent with the idea that the superior side
effect profile of aripiprazole may be due to reduced D2 receptor upregulation in
the dorsal striatum (Inoue et al., 1997). This thesis expands on this hypothesis,
suggesting that D2 receptor functioning is important for determining how
aripiprazole reduces psychosis and has fewer extrapyramidal effects.
Specifically, haloperidol and aripiprazole both act to alter the affinity of D2
receptors, which may explain their therapeutic effects in reducing the positive
symptoms of schizophrenia. Additionally, upregulation of D2 receptors and, in
turn, upregulation of proteins in the cAMP and Akt pathways may be partially
responsible for side effects. However, making comparisons between animal
studies and humans with schizophrenia is complicated, because the cellular
environment differs substantially between rats and clinical populations (Pan et
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al., 2016a). The cellular environment is important because aripiprazole is thought
to have either agonist or antagonist actions depending on the level of
dopaminergic activity which, of course, differs according to disease state and the
brain areas being assessed (Pan et al., 2016b). Despite this caution, the results
of this thesis indicate that aripiprazole does not affect the cAMP and Akt systems
as intensely as haloperidol.
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